Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
25 March 2026
Read original ↗
🅇 This trial is currently recruiting participants in the UK
Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.
🔬 This trial is currently recruiting participants
If you match the criteria below, you may be able to take part. Ask your doctor about this trial or contact the trial team directly.
Status
Recruiting
Trial Phase
PHASE2
Who Can Join
ALL
Age Range
29 Days – 17 Years
About This Trial
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Run by
Merck Sharp & Dohme LLC
⚕️ Before you apply: Talk to your GP or specialist about whether this trial might be right for you. Never stop existing treatment without medical advice. Trial ID: NCT05714085